Artelo Biosciences (ARTL) News Today $1.17 +0.02 (+1.74%) (As of 01:30 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Artelo Biosciences to present key data on 3 development programsNovember 18 at 4:27 PM | markets.businessinsider.comArtelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development SummitNovember 18 at 8:30 AM | globenewswire.comEquities Analysts Set Expectations for ARTL FY2024 EarningsNovember 18 at 2:47 AM | americanbankingnews.comArtelo Biosciences (NASDAQ:ARTL) Receives "Buy" Rating from HC WainwrightNovember 17, 2024 | americanbankingnews.comShort Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Declines By 26.8%November 14, 2024 | americanbankingnews.comArtelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration SymposiumNovember 13, 2024 | globenewswire.comArtelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” ProgramNovember 5, 2024 | globenewswire.comArtelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16thOctober 9, 2024 | globenewswire.comArtelo Biosciences shares initiated with Buy by EF HuttonOctober 3, 2024 | uk.investing.comBuy Rating on Artelo Biosciences Amidst Promising Clinical Advancements and Portfolio DiversificationSeptember 11, 2024 | markets.businessinsider.comArtelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comArtelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 13, 2024 | globenewswire.comArtelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 InhibitorJuly 15, 2024 | globenewswire.comArtelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society SymposiumJuly 3, 2024 | globenewswire.comArtelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain SocietyJune 4, 2024 | globenewswire.comArtelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24May 29, 2024 | globenewswire.comArtelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | finance.yahoo.comArtelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | globenewswire.comArtelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14thMay 10, 2024 | globenewswire.comArtelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer TherapyApril 23, 2024 | globenewswire.comArtelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern TimeApril 22, 2024 | globenewswire.comRecap: Artelo Biosciences Q4 EarningsMarch 25, 2024 | benzinga.comArtelo Biosciences GAAP EPS of -$3.14 misses by $0.58March 25, 2024 | msn.comArtelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateMarch 25, 2024 | globenewswire.comArtelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation ChallengeMarch 12, 2024 | globenewswire.comArtelo Biosciences, Inc.: Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thFebruary 15, 2024 | finanznachrichten.deArtelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12January 8, 2024 | finance.yahoo.comArtelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in GermanyDecember 5, 2023 | finance.yahoo.comPromising Developments in Artelo Biosciences’ Cancer Therapies Drive Buy Rating RecommendationNovember 16, 2023 | markets.businessinsider.comArtelo Biosciences GAAP EPS of -$0.83 misses by $0.18November 13, 2023 | msn.comArtelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 13, 2023 | finance.yahoo.comArtelo Biosciences Inc ARTLNovember 7, 2023 | morningstar.comArtelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023November 2, 2023 | finance.yahoo.comArtelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13thSeptember 5, 2023 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR), Artelo Biosciences (ARTL) and Unity Biotechnology (UBX)August 11, 2023 | markets.businessinsider.comArtelo Biosciences (ARTL) Receives a Buy from Ladenburg Thalmann & Co.June 28, 2023 | markets.businessinsider.comArtelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic PainJune 27, 2023 | msn.comArtelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society SymposiumJune 27, 2023 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL), Iterum Therapeutics (ITRM) and TScan Therapeutics (TCRX)May 18, 2023 | markets.businessinsider.comArtelo Biosciences: Q1 Earnings InsightsMay 11, 2023 | msn.comArtelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 11, 2023 | finance.yahoo.comArtelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossApril 25, 2023 | finance.yahoo.comArtelo Biosciences (ARTL) Gets a Buy from Maxim GroupApril 4, 2023 | markets.businessinsider.comArtelo Biosciences (ARTL) Gets a Buy from Ladenburg Thalmann & Co.April 3, 2023 | markets.businessinsider.comArtelo Biosciences GAAP EPS of -$3.56April 2, 2023 | seekingalpha.comArtelo Biosciences to Present at MicroCap Rodeo’s Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023February 15, 2023 | finance.yahoo.comArtelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 8, 2022 | finance.yahoo.comArtelo Biosciences to Present at The LD Micro Main Event XVOctober 18, 2022 | finance.yahoo.comARTL Artelo Biosciences, Inc.October 11, 2022 | seekingalpha.comArtelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29thSeptember 22, 2022 | finance.yahoo.com Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide ARTL Media Mentions By Week ARTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARTL News Sentiment▼0.090.47▲Average Medical News Sentiment ARTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARTL Articles This Week▼70▲ARTL Articles Average Week Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kazia Therapeutics News NRx Pharmaceuticals News AIM ImmunoTech News Sol-Gel Technologies News NLS Pharmaceutics News Sensei Biotherapeutics News Talphera News NKGen Biotech News Aspira Women's Health News Turnstone Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARTL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
